September 26, 2011 -- Guangdong Zhongsheng Pharma will spend 20 million RMB ($3.1 million) to develop three new drugs to treat pulmonary fibrosis, diabetes and solid-tumor cancers in cooperation with Sichuan University and Guangdong South China Center for Innovative Pharmaceuticals. Zhongsheng Pharma owns the IP for the drugs, which have completed their pre-clinical development. More details....
Stock Symbol: (SHE: 002317)
